Fluid management: the pharmacoeconomic dimension.
Cost is a key concern in fluid management. Relatively few data are available that address the comparative total costs of care between different fluid management regimens in particular clinical indications. Relevant costs of fluid-associated morbidity and mortality, including those incurred after intensive care unit or hospital discharge, also need to be considered in evaluating the cost-benefit ratios of administered fluids. Rigorously designed pharmacoeconomic studies are needed to delineate the costs and benefits of various approaches to fluid management.
Université Libre de Bruxelles, Brussels, Belgium. jlvincen@ulb.ac.be
J L
JL
Vincent
D003362:Cost-Benefit Analysis; D005440:Fluid Therapy / Q000191:economics* / Q000379:methods*; D006801:Humans; D009017:Morbidity; D009026:Mortality; D015532:Rehydration Solutions / Q000191:economics* / Q000627:therapeutic use; D012709:Serum Albumin / Q000191:economics* / Q000627:therapeutic use
D015532:Rehydration Solutions; D012709:Serum Albumin